2,9-dimethyl-beta-carbolinium has been researched along with Parkinson Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akane, A; Collins, MA; Ikebuchi, J; Kagawa, M; Matsubara, K; Neafsey, EJ; Shiono, H | 1 |
| Awaya, T; Chiba, K; Hayase, N; Kimura, K; Matsubara, K; Ogawa, S; Senda, T; Shimizu, K; Uezono, T | 1 |
2 other study(ies) available for 2,9-dimethyl-beta-carbolinium and Parkinson Disease
| Article | Year |
|---|---|
Potential bioactivated neurotoxicants, N-methylated beta-carbolinium ions, are present in human brain.
Topics: Brain Chemistry; Carbolines; Chromatography, High Pressure Liquid; Gas Chromatography-Mass Spectrometry; Humans; Molecular Structure; Neurotoxins; Parkinson Disease | 1993 |
L-Deprenyl prevents the cell hypoxia induced by dopaminergic neurotoxins, MPP(+) and beta-carbolinium: a microdialysis study in rats.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Carbolines; Cell Hypoxia; Dopamine; Dose-Response Relationship, Drug; Extracellular Space; Herbicides; Lactic Acid; Male; Microdialysis; Mitochondria; Monoamine Oxidase Inhibitors; Neostriatum; Neurons; Neuroprotective Agents; Neurotoxins; Pargyline; Parkinson Disease; Rats; Rats, Wistar; Selegiline | 2001 |